MASLD 肝纤维化筛查:证据、挑战与影像的作用
本文为 AJR 特别系列综述,梳理代谢功能障碍相关脂肪性肝病(MASLD)肝纤维化筛查的现状。重点关注影像在筛查流程中作为二线评估手段的作用、风险分层与管理决策价值。
要点
- MASLD 患者出现临床显著纤维化后才明显增加肝脏不良结局风险
- 筛查一般先做血液检测,二线影像检查用于验证纤维化并风险分层
- 影像报告应结合纤维化分期判断是否需专科转诊或监测
核心结论
- 影像在 MASLD 肝纤维化筛查中承担二线评估作用,主要用于验证临床显著或进展期纤维化并辅助风险分层和管理决策
研究设计与样本
- 本文为 AJR 特别系列综述,未报告具体样本量
- 综述聚焦成人 MASLD 肝纤维化筛查的现有证据与最佳实践
诊断标准与关键数值
- 临床显著纤维化定义为组织学纤维化分期为 2 期或 3 期
- 进展期纤维化定义为组织学纤维化分期为 3 期及以上
- 肝硬化定义为组织学纤维化分期为 4 期
临床应用与阅片要点
- 高风险人群筛查包括糖尿病患者、具有其他心脏代谢危险因素者或偶然检出脂肪肝者
- 筛查流程以血液检测为一线,非侵入性影像可作为二线评估手段
- 2 或 3 期非肝硬化纤维化患者可能适合药物干预以预防进展为肝硬化
- 3 期及以上纤维化通常需要更严密监测
- 4 期肝硬化患者需额外支持治疗及食管胃底静脉曲张和原发性肝癌监测
局限性
- 该综述未报告检索策略、纳入文献数量及证据分级方法
- 关于影像诊断敏感度、特异度、AUC 及具体阈值,原文未提供可提取数据
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 40% of the world's population. Despite an association with increased cardiovascular morbidity, MASLD usually does not lead to liver-related adverse outcomes until fibrosis develops. MASLD with clinically significant fibrosis (histologic fibrosis stage ≤2) is associated with poorer prognosis and helps guide management, including specialty care referral. Among adults with MASLD, those with noncirrhotic clinically significant fibrosis (stage 2 or 3) may be eligible for pharmacotherapy to prevent progression to cirrhosis; those with advanced fibrosis (stage ≤3) usually require intensive monitoring; and those with cirrhosis (stage 4) may require additional supportive therapy and surveillance for gastroesophageal varices or primary liver cancer. Professional societies now recommend selective screening of high-risk patients to detect MASLD with clinically significant or advanced fibrosis. While guideline details vary, the screening population generally includes those with diabetes, other cardiometabolic factors, or incidentally detected steatosis. Screening begins with blood-based tests; second-line assessment, possibly including noninvasive imaging, seeks to verify MASLD with clinically significant or advanced fibrosis, stratify risk, and inform management. This Special Series Review describes current and best practices for screening adults to detect and stratify MASLD, focusing on imaging's critical and evolving role in addressing this public health challenge.
引用
- Chan, Hong, Ceriani, et al. Screening for Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence, Challenges, and the Role of Imaging-From the AJR Special Series on Screening. AJR Am J Roentgenol. 2026. PMID: 42524736. doi:10.2214/AJR.26.34836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。